COMPANY

Aprea Therapeutics

Aprea Therapeutics is listed on ClinicalTrials.gov as the lead sponsor of 12 studies; the most recently updated is “Study of APR-1051 in Patients With Advanced Solid Tumors” (Phase 1, recruiting), in Advanced Solid Tumor. Aprea Therapeutics has received NIH funding, most recently in fiscal 2024 for the project “Development of a first-in-class combination of DNA damage response inhibitors for the treatment of high-grade serous ovarian cancer”. From public records Source · Oct 12, 2026

Keywords: Tumors ; cancer Bladder Cancer Gastric Cancer Non Small Cell Lung Cancer NSCLC Urothelial Carcinoma Non Hodgkin Lymphoma Chronic Lymphocytic Leukemia Mantle Cell Lymphoma Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53 Myeloid Malignancy High-grade Serous Ovarian Cancer Myelodysplastic Syndromes Hematologic Neoplasms Prostatic Neoplasms Melanoma APR-246 ATRN-119

Location: Doylestown, PA · source · Oct 14, 2026

Profile checked Oct 10, 2026

$30.0MRaised (2 yrs)12Trials (company is sponsor)

Funding and NIH signals

SEC Form D raise Raised $3.06M (Form D filed Dec 29, 2025). SEC Form D 0001781983-25-000003 (Dec 29, 2025)
Evidence (1 event)
- Dec 29, 2025 · SEC Form D 0001781983-25-000003
  Name of Issuer: Aprea Therapeutics, Inc.; CIK: 1781983; Address: Doylestown, PA; Submission type: D; Filing date: 2025-12-29; Industry Group: Biotechnology; Date of First Sale: 2025-12-10; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 5783766; Total Amount Sold: 3055822; Federal exemptions: 06b

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

Apr 1, 2026 Raise Private placement: $30M (total, as published), announced Apr 1, 2026. Source: company release on GlobeNewswire. source ↗
Jun 13, 2024 Trial start Phase 1: Study of APR-1051 in Patients With Advanced Solid Tumors source ↗
Jan 9, 2023 Trial start Phase 1/Phase 2: Study Of ATRN-119 In Patients With Advanced Solid Tumors source ↗
Sep 20, 2021 Trial start Phase 1: APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS) source ↗
Mar 2, 2021 Trial start Phase 1/Phase 2: APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL) source ↗
Jun 25, 2020 Trial start 1: Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies source ↗
Dec 13, 2019 Trial start Phase 1: APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies source ↗
Sep 16, 2019 Trial start Phase 2: APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant source ↗
Jan 11, 2019 Trial start Phase 3: APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS) source ↗
Jan 18, 2018 Trial start Phase 1/Phase 2: A Study of APR-246 in Combination With Dabrafenib in Resistant Patients With BRAF V600 Mutant Melanoma source ↗
Jul 31, 2017 Trial start Phase 2: p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246 source ↗
2014-03 Trial start I: p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246 source ↗
2009-05 Trial start Phase 1: Safety Study of APR-246 in Patients With Refractory Hematologic Cancer or Prostate Cancer source ↗

Upcoming milestones

2027-06 (ESTIMATED) · Phase 1 · Study of APR-1051 in Patients With Advanced Solid Tumors · NCT06260514

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $30.0M. Last 2 years.

Apr 1, 2026 Private placement: $30M (total, as published), announced Apr 1, 2026. Source: company release on GlobeNewswire. source ↗

Clinical trials (lead sponsor) 12

Record	Title	Phase	Status	Start	Primary completion
NCT06260514	Study of APR-1051 in Patients With Advanced Solid Tumors	Phase 1	Recruiting	Jun 13, 2024	2027-06 (estimated)
NCT04905914	Study Of ATRN-119 In Patients With Advanced Solid Tumors	Phase 1/Phase 2	Completed	Jan 9, 2023	Mar 9, 2026 (actual)
NCT04383938	Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies	1	Completed	Jun 25, 2020	Apr 30, 2022 (actual)
NCT03745716	APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)	Phase 3	Completed	Jan 11, 2019	Nov 27, 2020 (actual)
NCT03931291	APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant	Phase 2	Completed	Sep 16, 2019	Aug 27, 2021 (actual)
NCT04419389	APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)	Phase 1/Phase 2	Terminated	Mar 2, 2021	Aug 23, 2021 (actual)
NCT02098343	p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246	I	Completed	2014-03	2019-04 (actual)
NCT04214860	APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies	Phase 1	Completed	Dec 13, 2019	Jan 14, 2022 (actual)
NCT03268382	p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246	Phase 2	Completed	Jul 31, 2017	Jul 10, 2019 (actual)
NCT04638309	APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS)	Phase 1	Terminated	Sep 20, 2021	Apr 25, 2022 (actual)
NCT00900614	Safety Study of APR-246 in Patients With Refractory Hematologic Cancer or Prostate Cancer	Phase 1	Completed	2009-05	2010-10 (actual)
NCT03391050	A Study of APR-246 in Combination With Dabrafenib in Resistant Patients With BRAF V600 Mutant Melanoma	Phase 1/Phase 2	Terminated	Jan 18, 2018	Aug 8, 2018 (actual)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

2025-12-29 Raise Private raise (SEC Form D): $3.1M sold of $5.8M offered; issuer “Aprea Therapeutics, Inc.”. Verified from the SEC filing. SEC filing ↗